Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients

Table 6

Viral infection and allograft rejection (AR) in DES and non-DES patients.

Allograft rejection (AR)	Kidney transplant patients		value
	DES group ( = 363)	Non-DES group ( = 497)
AR, (%)
Any AR	68 (18.7)	70 (14.1)	0.07
ABMR	44 (12.1)	11 (2.2)	<0.001
CMR	41 (11.3)	68 (13.7)	0.35
CMV, EBV, or BKV viremia, (%)	80 (22.0)	138 (27.8)	0.06
AR within 6 months after VI, (%)
Any AR after VI	15/80 (18.8)	16/138 (11.6)	0.16
ABMR after VI	8/80 (10.0)	3/138 (2.2)	0.02
CMR after VI	11/80 (13.8)	15/138 (10.9)	0.52

Viremia (VI) with peak levels > 50 copies/PCR for CMV & EBV and >2500 copies/ml for BKV viremia was analyzed.
The comparison between the two groups was performed by Fisher’s exact test.